Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 07 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Lenalidomide Capsules in two dosages. These capsules are intended for treating various cancers and certain blood disorders, and will soon be launched in the US market. The manufacturing will take place at Zydus's facility in Ahmedabad, India. This approval adds to Zydus's growing portfolio, which now includes a significant number of approvals since the filing process began.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases